PSC 833是P-gp-mediated MDR的抑制剂。
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Song et al (1998) Modulation of the tumor disposition of vinca alkaloids by PSC 833 in vitro and in vivo. J.Pharmacol.Exp.Ther. 287 963. PMID: 9864280.
[2] Goda et al (2007) Complete inhibition of P-glycoprotein by simulataneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J.Pharmacol.Exp.Ther. 320 81. PMID: 17050779.
[3] Shen et al (2008) Quantitation of doxorubicine uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J.Pharmacol.Exp.Ther. 324 95. PMID: 17947497.
[4] Shen et al (2009) Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by Valspodar (PSC833) in multidrug resistance human cancer cells. J.Pharmacol.Exp.Ther. 330 423. PMID: 19423841.
分子式 C63H111N11O12 |
分子量 1214.62 |
CAS号 121584-18-7 |
储存方式 ﹣20 ℃长期储存。冰袋运输 |
溶剂(常温) |
DMSO 4 mM |
Water |
Ethanol |
体内溶解度
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们